Newsletter Tool

Featured Story

The top 10 biotech IPOs of 2021

By Annalee Armstrong

The IPO market started off blazing hot in 2021, but valuations and interest began to cool toward the end of the year. We still saw a record-breaking 100 listings, with more and more companies filing for the public markets before producing even a shred of data.

The top 10 medtech IPOs of 2021

By Conor Hale

The second year of the COVID-19 pandemic saw a wave of global demand for coronavirus tests and telehealth that finally reached the public markets. But all waves ebb and flow, and many companies may have seen their stock value crest early in 2021.

GlaxoSmithKline unveils Haleon, the new brand name for its outgoing consumer health unit

By Angus Liu

CEO, check. Chairman, check. A new headquarters, being planned. And GlaxoSmithKline now has a new name for its consumer health unit.

FTC, Rhode Island move to block Lifespan, Care New England merger

By Dave Muoio

The federal regulator and Rhode Island's attorney general agreed that the deal would lead to "extraordinary" market power, likely raising prices and reducing the quality of care across the state and into some nearby Massachusetts communities.

Biotech IPOs in the current market environment? Experts say it's 'a bit silly, if not suicidal'

By Kyle LaHucik

2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence. And they paid for it.

Medtronic's earnings flatten out as COVID pandemic, healthcare worker shortage rage on

By Andrea Park

For the latest quarter, Medtronic raked in $7.76 billion, about 1% lower than the previous quarter’s haul and 0.2% below its earnings for the same period in 2021.

Biohaven lines up rhinosinusitis patients for trial of its migraine med Nurtec ODT

By Kevin Dunleavy

Biohaven has a blockbuster-to-be in migraine med Nurtec ODT. Now the company has another indication in mind for the treatment—rhinosinusitis. The company revealed that it is lining up participants for a phase 2/3 trial of Nurtec in those with chronic rhinosinusitis.

Payers, Medicaid officials ask Congress for 120-day glide path to end of COVID-19 emergency

By Robert King

A group of payers and state Medicaid officials want a 120-day notice from Congress when the COVID-19 public health emergency will end, warning that the redeterminations of Medicaid eligibility will be a massive operational challenge.

Moderna's RSV shot sails on to phase 3, tightening Big Pharma battle royale

By Annalee Armstrong

Moderna’s RSV vaccine candidate is heading for phase 3 after an independent safety review cleared the shot to advance. The decision is based on data from a phase 2 trial, called ConquerRSV, which found the vaccine to be safe and tolerable at the selected dose.

Novartis' Leqvio to reap $2.5B by 2027 thanks to convenience edge over Amgen, Sanofi rivals: analyst

By Kevin Dunleavy

Novartis' new cholesterol-lowering drug Leqvio could reach sales of $2.5 billion by 2027, according to GlobalData, thanks largely to its ease of administration. The data analytics firm sees Leqvio surpassing its PCSK9 predecessors, Amgen’s Repatha and Sanofi and Regeneron’s Praluent, which will project to ring up sales of $2.2 billion and $716 million respectively.

Digital psychiatry startup Minded grabs $25M to boost access to mental health medications

By Rebecca Torrence

Digital psychiatry startup Minded raised $25 million in seed funding to ease access to prescription medications for mental health conditions through its telehealth platform.

Baxter warns of potential blockages in infusion pumps linked to 3 deaths